Capricor Therapeutics Inc (NASDAQ:CAPR) Given Average Rating of “Buy” by Brokerages

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $34.50.

CAPR has been the topic of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group increased their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Piper Sandler started coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. Cantor Fitzgerald raised their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, November 14th.

Capricor Therapeutics Trading Up 0.3 %

Shares of CAPR stock opened at $13.80 on Thursday. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The business’s 50 day moving average is $16.95 and its two-hundred day moving average is $10.78. The company has a market capitalization of $627.49 million, a P/E ratio of -13.02 and a beta of 3.98.

Institutional Trading of Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. Main Street Financial Solutions LLC increased its position in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $133,000. Bank of New York Mellon Corp increased its holdings in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in Capricor Therapeutics in the third quarter valued at approximately $192,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.